Clinical Committee Co-Chairs
Professor Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, England
Professor Wim Oyen is Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, and Consultant in Nuclear Medicine and Head of the Department of Nuclear Medicine at The Royal Marsden NHS Foundation Trust. He leads a programme to translate new radiopharmaceuticals developed at the ICR into clinical studies at The Royal Marsden and to introduce novel molecular imaging approaches for staging, treatment selection and monitoring of treatment response, as a means of optimising therapy for the individual cancer patient.
He is author on more than 600 articles in scientific journals, including Lancet Oncology, Nature Reviews Clinical Oncology and The Journal of Clinical Oncology, and more than 100 papers in The Journal of Nuclear Medicine. The scientific work of his group was awarded with The Marie Curie Award of the European Association of Nuclear Medicine in 1994 and in 2011. He was awarded with honorary membership of the European Society for Radiotherapy and Oncology in 2009.
Currently, he sits on the Board of the European Cancer Organisation (ECCO) and has served on the Board of the European Association of Nuclear Medicine (EANM) as the Congress Chair 2014-2016. As of January 2017, Professor Oyen is EANM President-elect and will start the two-year presidential term in 2019. He is actively involved in the European Organisation for Research and Treatment of Cancer (EORTC). He serves as Associate Editor of The Journal of Nuclear Medicine and is a member of the editorial board of the European Journal of Nuclear Medicine and Molecular Imaging and other international imaging journals.
Dr. Lionel S. Zuckier, MD, MBA, FRCPC, Professor and Medicine and Radiology, University of Ottawa and Director of Research, Division of Nuclear Medicine, The Ottawa Hospital, Ottawa Canada.
Lionel Zuckier MD, MBA, FRCPC, is Professor of Medicine and Radiology at University of Ottawa and Division Head Emeritus of the Division of Nuclear Medicine at the Ottawa Hospital. His current responsibilities include Director of Research in Nuclear Medicine and Chair of the Institutional Radiation Safety Committee. Dr. Zuckier trained in nuclear medicine and radiology at the Albert Einstein College of Medicine in New York where he also studied B-cell immunology and the targeting of tumours with radiolabeled immunologic moieties following receipt of a NIH Physician Scientist Training Award. He has published over 90 articles in research and review journals, authored multiple book chapters, and coedited several textbooks. Dr. Zuckier has participated in numerous imaging and therapeutic trials, including involvement in trials of Ra-223 for the treatment of boney metastases in prostate cancer, for which The Ottawa Hospital was an early research participant and clinical training site for other centres. Dr. Zuckier has organized symposia on radionuclide therapy of bone metastases and on the emergency response to radiation accidents. He has served as an examiner for the American Board of Radiology and the Royal College of Physicians and Surgeons of Canada, and currently is a member of Board of Directors of the Society of Nuclear Medicine and Molecular Imaging, General Clinical Nuclear Medicine Council.
Dr. Michael Morris
Dr. Morris is a clinical investigator with the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, which he is Section Head of Prostate Cancer and is the Clinical Director. He earned his medical degree from the Mount Sinai School of Medicine in New York, performed his internship and residency in internal medicine at New YorkPresbyterian/Columbia University Medical Center, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Since then, he has been on faculty at MSKCC in the GU Oncology Service, with a research focus on developing
novel therapies and imaging biomarkers for metastatic prostate cancer.
Dr. Morris has been the PI of numerous clinical trials, but has a particular research focus on targeted therapy for prostate cancer, in particular those that bridge the fields of medical oncology and nuclear medicine. From a therapeutic standpoint, he has had a particular focus on radioimmunotherapy and other radio-conjugates, bone directed therapy, and tumor-targeted therapies. He also has a keen research interest in developing novel imaging technologies for metastatic prostate cancer, especially in regards to testing them as validated biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET imaging and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Defense/PCF Prostate Cancer Clinical Consortium, and Chairs the GU Committee of the NCI cooperative group, Alliance for Oncology Trials in Oncology.
Dr. Eugene Leung
Dr. Leung received his MD from the University of Ottawa. After completing residency dedicated to Nuclear Medicine at the University of Western Ontario, he received specialist certification from the Royal College of Physicians and Surgeons of Canada, the American Board of Nuclear Medicine, and the Certification Board of Nuclear Cardiology. Following a fellowship in radioisotope therapy, Dr. Leung joined as a full-time member of the Division of Nuclear Medicine at The Ottawa Hospital in 2007 and practices broadly in all aspects of Nuclear Medicine, including cardiac, PET, bone densitometry, and therapy. He is an assistant professor at the University of Ottawa, Clinical Investigator at the Ottawa Hospital Research Institute and has served as Director of Patient Quality and Safety in his Division.
Dr. Leung is enthusiastically committed to the rapidly evolving field of functional imaging and theranostics. He enjoys broadening the understanding of this dynamic specialty to the public, medical students, residents, technologists, and colleagues alike through education, collaboration and research. He has lectured abroad and published on specific clinical interests such as PET imaging of cardiac sarcoidosis. He is a board examiner for Canadian diplomates through the Royal College and at the Kuwait Institute for Medical Specialization through the Royal College outreach program. He collaborates closely with multiple specialties to share his expertise in radioisotope therapy, co-chairs of the TOH Thyroid tumor board, and has directed research studies and transitioned to clinical practice the treatment of bone metastases using radium-223.
Professor Joe O’Sullivan
Joe O’Sullivan is a Prostate Cancer Oncologist at the Northern Ireland Cancer Centre, and Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University Belfast.
Joe graduated from University College Dublin medical School in 1993 and trained in Radiation Oncology in St. Luke’s Hospital in Dublin. In 2000 he took up a Clinical research Fellowship at the Royal Marsden London, completing a Doctorate Thesis on the use of high doses of Rhenium-186HEDP with stem cell support in advanced prostate cancer. He was appointed as a senior lecturer and consultant clinical oncologist to Queen’s University Belfast in 2004 and was subsequently appointed as Professor of Radiation Oncology in 2011. He was served as Clinical Director of Oncology at The Northern Ireland Cancer Centre, Belfast in 2014-2017.
His research interests include bone-seeking radionuclide therapy in metastatic prostate cancer, translational research in prostate cancer and radiotherapy, and clinical trials in advanced prostate cancer and he has published over 100 research papers. He is one the 4 Directors of the FASTMAN Prostate Cancer Centre of Excellence (Belfast and Manchester) which is 5-year programme of research awarded in 2014 and funded by Movember and PCUK
Dr. Scott Morgan
Dr. Morgan is a radiation oncologist at The Ottawa Hospital Cancer Centre and an Assistant Professor in the Division of Radiation Oncology at the University of Ottawa. He holds a Bachelor of Applied Science in Engineering Physics from the University of British Columbia, a Doctor of Medicine from Queen’s University, and a Master of Science in Clinical Trials from the University of London. Prior to starting his practice in Ottawa in 2010, he completed a fellowship in genitourinary clinical oncology at The Royal Marsden Hospital in London. His practice is focused on genitourinary and breast malignancy, and he has a research interest in therapies for prostate cancer across its spectrum from localized to advanced disease. He is a longstanding member of the Genitourinary Disease Site Group of the Cancer Care Ontario Programme in Evidence-Based Care. Since 2016, he has served as Co-Chair of the Genitourinary Guideline Advisory Group of the American Society of Clinical Oncology.
Dr. Ran Klein, PhD
Ran Klein holds a PhD in Electrical Engineering and is Imaging Physicist at The Ottawa Hospital, Department of Nuclear Medicine. He was previously a Research Associate at the University of Ottawa Heart Institute, National Cardiac PET Centre, where he also managed the Cardiac Imaging Core Lab. He has over 15 years research experience in Nuclear Medicine that produced over 100 publications and abstracts. His research is focused on extracting quantitative, physiologic information from cardiac images. His greatest impact has been on quantification of myocardial blood flow using rubidium-82 positron emission tomography which is applied clinically internationally. His research has resulted in commercially available software for image analysis (FlowQuant). Ran’s work on an automated rubidium-82 infusion system is currently being commercialized by Jubilant-DraxImage, Montreal, Quebec. His current interests include quantitative medical imaging and computer aided diagnosis. He is an assistant professor at the University of Ottawa, Department of Medicine, and is also an adjunct professor at Carleton University, Department of Systems and Computer Engineering and at the Department of Physics.
Dr. Neeta Pandit-Taskar
Dr. Pandit-Taskar is a clinician-scientist who is board certified in nuclear medicine and nuclear cardiology. She has more than two decades of broad experience in clinical nuclear medicine and related research. Dr. Pandit-Taskar joined MSK in 2000 and is also Clinical Director of the Center for Radioimmunotargeted Imaging and Theranostics of the Ludwig Center for Cancer immunotherapy. Before coming to MSK, she was head of the nuclear medicine department at a cancer center in India.